Mercados españoles cerrados en 1 hr 58 mins

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
275,94+2,11 (+0,77%)
A partir del 09:32AM EST. Mercado abierto.

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Sector(es)Healthcare
SectorDrug Manufacturers - General
Empleados a tiempo completo26.700

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Robert A. BradwayChairman, CEO & President5,49MN/A1963
Mr. Peter H. GriffithExecutive VP & CFO2,57MN/A1959
Mr. Esteban SantosExecutive Vice President of Operations2,52MN/A1968
Dr. David M. Reese M.D.Executive VP & Chief Technology Officer2,83MN/A1963
Mr. Murdo GordonExecutive Vice President of Global Commercial Operations2,72MN/A1967
Mr. Matthew C. BuschChief Accounting Officer & VP of FinanceN/AN/A1974
Mr. Mike ZahigianSenior VP & Chief Information OfficerN/AN/AN/A
Dr. James E. Bradner M.D.Executive VP of Research and Development & Chief Scientific OfficerN/AN/A1972
Mr. Jonathan P. GrahamExecutive VP, General Counsel & Secretary2,44MN/A1961
Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and Chief Compliance OfficerN/AN/A1968
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gobierno corporativo

El ISS Governance QualityScore de Amgen Inc., a día 28 de febrero de 2024, es 3. Las puntuaciones base son Auditoría: 4; Tablero: 9; Derechos de los accionistas: 1; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.